Eli Lilly cutting cost of certain weight loss drugs by at least 50%
FILE-The Eli Lilly headquarters in Indianapolis, Indiana, on Thursday, Aug. 15, 2024. (AJ Mast/Bloomberg via Getty Images)
Eli Lilly is slashing the cost of certain weight loss drugs and selling them for half the price of other drugs.
The pharmaceutical company said Tuesday that it is offering 2.5 mg and 5 mg single-dose vials of tirzepatide, sold under the brand name Zepbound, based on growing demand from consumers.
Eli Lilly tells FOX Business that the new single doses are priced at a 50% or greater discount compared to the list price of all other GLP-1 medicines for obesity.
RELATED: FDA approves Eli Lilly's Alzheimer's drug that can modestly slow disease
According to FOX Business, GLP-1 agonists are a class of Type 2 diabetes drugs that improve blood sugar control but may also lead to weight loss. Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic, as well as tirzepatide, are considered GLP-1 drugs.
The drug company tells FOX business that the extra supply will help adults with obesity gain access to the medication they need, this includes people ineligible for the Zepbound savings card program, individuals without employer coverage and those who are paying outside of insurance.
Eli Lilly conducted a recent clinical trial that found that weekly shots of tirzepatide injections lowered the risk of progression to Type 2 diabetes by 94% among adults with pre-diabetes and obesity compared to the placebo.
In June, health officials issued warnings about fraudulent versions of popular weight-loss and diabetes medications. Eli Lilly expressed their concerns in an open letter about the rise in fake or compounded versions of tirzepatide, which is used in its drugs Mounjaro and Zepbound. The company highlighted the danger of these fake drugs being promoted and sold online.
Meanwhile, the World Health Organization revealed that it has received multiple reports of fake semaglutide distributed in parts of the world since 2022.